Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
CJC-1295 (no DAC) (CJC) is a growth hormone peptide, at the clinical trials stage in the published literature. Modified Growth Hormone Releasing Factor (1-29) that provides more stable GH release when combined with GHRPs. Also known as Mod GRF 1-29.
Modified Growth Hormone Releasing Factor (1-29) that provides more stable GH release when combined with GHRPs. Also known as Mod GRF 1-29.
| Research Status | Clinical trials |
|---|---|
| Half-Life | 30 minutes |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 100-200 mcg |
GHRH receptor agonist that stimulates pituitary to release GH in a pulsatile manner, synergizes with GHRPs.
Modified Growth Hormone Releasing Factor (1-29) that provides more stable GH release when combined with GHRPs. Also known as Mod GRF 1-29.
GHRH receptor agonist that stimulates pituitary to release GH in a pulsatile manner, synergizes with GHRPs.
CJC-1295 (no DAC) is at the following stage in the published literature: Clinical trials. All information is for research and educational purposes only.
Reported half-life: 30 minutes.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.